Krystal Biotech (KRYS) Total Liabilities (2016 - 2026)

Krystal Biotech has disclosed Total Liabilities across 11 years of filings, most recently posting $120.2 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $120.2 million, up 33.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $120.2 million (up 33.98% YoY), and the FY2025 annual result was $114.2 million, up 4.36% from the prior year.
• Total Liabilities came in at $120.2 million for Q1 2026 at Krystal Biotech, up from $114.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $120.2 million in Q1 2026 to a low of $30.9 million in Q2 2023.
• The 5-year median for Total Liabilities is $68.3 million (2022), against an average of $70.1 million.
• Across the five-year window, Total Liabilities jumped 452.48% in 2022 and sank 38.11% in 2023, its largest moves.
• Krystal Biotech's Total Liabilities stood at $36.2 million in 2022, then gained by 9.65% to $39.7 million in 2023, then jumped by 175.62% to $109.5 million in 2024, then rose by 4.36% to $114.2 million in 2025, then climbed by 5.26% to $120.2 million in 2026.
• The last three Total Liabilities figures came in at $120.2 million (Q1 2026), $114.2 million (Q4 2025), and $102.2 million (Q3 2025), per Business Quant data.